Marinomed Biotech AG (WBO:MARI) LT-Debt-to-Total-Asset : 1.74 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Marinomed Biotech AG LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Marinomed Biotech AG's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 1.74.

Marinomed Biotech AG's long-term debt to total assets ratio increased from Mar. 2023 (1.03) to Mar. 2024 (1.74). It may suggest that Marinomed Biotech AG is progressively becoming more dependent on debt to grow their business.

Marinomed Biotech AG LT-Debt-to-Total-Asset Historical Data

The historical data trend for Marinomed Biotech AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinomed Biotech AG LT-Debt-to-Total-Asset Chart

Marinomed Biotech AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.23

0.53

0.71

0.91

1.02

Marinomed Biotech AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															1.03	1.09	1.28	1.02	1.74

Marinomed Biotech AG LT-Debt-to-Total-Asset Calculation

Marinomed Biotech AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	14.84	/	14.612
	=	1.02

Marinomed Biotech AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	21.15	/	12.148
	=	1.74

Marinomed Biotech AG (WBO:MARI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Marinomed Biotech AG LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Marinomed Biotech AG's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinomed Biotech AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinomed Biotech AG (WBO:MARI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

93Z:Germany

Address

Hovengasse 25, Korneuburg, AUT, 2100

Website

https://www.marinomed.com

Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.

Executives

Simon Nebel	Supervisory Board
Andreas Grassauer	Board of Directors
Eva Prieschl-grassauer	Board of Directors

Marinomed Biotech AG Headlines

No Headlines